Provided by Tiger Trade Technology Pte. Ltd.

60 degrees pharmaceuticals, Inc.

1.08
-0.0500-4.42%
Post-market: 1.080.00000.00%16:10 EDT
Volume:51.17K
Turnover:56.53K
Market Cap:3.80M
PE:-0.17
High:1.16
Open:1.13
Low:1.04
Close:1.13
52wk High:8.62
52wk Low:1.02
Shares:3.52M
Float Shares:1.77M
Volume Ratio:1.16
T/O Rate:2.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-6.3166
EPS(LYR):-11.7369
ROE:-332.85%
ROA:-127.13%
PB:-0.55
PE(LYR):-0.09

Loading ...

Analysts’ Opinions Are Mixed on These Healthcare Stocks: OmniAb (OABI), Bicycle Therapeutics (BCYC) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Aug 17

60 Degrees Pharmaceuticals Q2 EPS USD -0.9

THOMSON REUTERS
·
Aug 15

60 Degrees Pharmaceuticals Q2 Operating Expenses USD 2.33 Million

THOMSON REUTERS
·
Aug 15

Press Release: 60 Degrees Pharmaceuticals Announces Second Quarter 2026 Results

Dow Jones
·
Aug 15

60 Degrees Pharma Q2 FY26 Net Loss Widens 30.6% to $2.26 Million; Revenue More than Doubles to $207,898

Reuters
·
Aug 15

60 Degrees Pharmaceuticals Holds Annual Shareholder Meeting

Reuters
·
Aug 07

60 Degrees Pharmaceuticals Issues Series A, Series B Warrants Exercisable at $1.49 in $1 Million Private Placement

Reuters
·
Aug 05

60 Degrees Pharmaceuticals Completes Private Placement to Raise Capital

TIPRANKS
·
Aug 05

60 Degrees Pharmaceuticals to sell shares and warrants in private placement

TIPRANKS
·
Jul 31

60 Degrees Pharmaceuticals, Inc. Announces Private Placement Priced at-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Jul 31

60 Degrees Pharma Hits Minimum Enrollment Trigger for Interim Readout in Severe Babesiosis Tafenoquine Trial

Reuters
·
Jul 30

60 Degrees Pharmaceuticals Files Form 3 Showing Knight Therapeutics Stake of 658,629 Shares

Reuters
·
Jul 30

60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026

THOMSON REUTERS
·
Jul 30

60 Degrees Pharmaceuticals - Company to Request FDA Meeting on Nda Pathway for Tafenoquine in Babesiosis

THOMSON REUTERS
·
Jul 30

60 Degrees updates strategy for ARAKODA and profitability

TIPRANKS
·
Jul 21

60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-borne Diseases

THOMSON REUTERS
·
Jul 08

60 Degrees Pharma Says DSMB Backs Continuing Phase 2 Tafenoquine Chronic Babesiosis Fatigue Study

Reuters
·
Jul 01

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-free Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

THOMSON REUTERS
·
Jul 01

60 Degrees Pharma CEO Geoffrey Dow acquires 7,350 common shares worth $10,130.24

Reuters
·
Jun 16

60 Degrees Pharmaceuticals Licenses Patent to Produce Australian Chestnut Extract

MT Newswires Live
·
Jun 11